STOCK TITAN

[144] 10x Genomics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

10x Genomics (TXG) filed a Form 144 reporting a proposed sale under Rule 144 of 7,393 shares of common stock with an aggregate market value of $99,140.13, planned on 08/22/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

The shares were acquired as a Restricted Stock Unit grant from the issuer on 08/21/2025 totaling 20,657 units and paid as services rendered. The filer also sold 7,485 shares on 05/22/2025 for gross proceeds of $62,120.26. The notice includes the standard representation that the selling person is not aware of undisclosed material adverse information.

10x Genomics (TXG) ha presentato un modulo 144 segnalando la prevista vendita, ai sensi della Rule 144, di 7.393 azioni ordinarie per un valore di mercato complessivo di $99.140,13, programmata per il 22/08/2025 su NASDAQ tramite Morgan Stanley Smith Barney LLC.

Le azioni sono state assegnate come Restricted Stock Unit dall'emittente il 21/08/2025 per un totale di 20.657 unità e corrisposte come compenso per servizi resi. Il dichiarante aveva inoltre venduto 7.485 azioni il 22/05/2025 per proventi lordi di $62.120,26. L'avviso include la consueta dichiarazione che la persona venditrice non è a conoscenza di informazioni riservate sfavorevoli non divulgate.

10x Genomics (TXG) presentó un Formulario 144 informando de la venta propuesta bajo la Regla 144 de 7.393 acciones ordinarias por un valor de mercado agregado de $99,140.13, prevista para el 22/08/2025 en NASDAQ a través de Morgan Stanley Smith Barney LLC.

Las acciones fueron otorgadas como Restricted Stock Unit por el emisor el 21/08/2025, por un total de 20.657 unidades y pagadas como compensación por servicios prestados. El declarante también vendió 7.485 acciones el 22/05/2025 por ingresos brutos de $62.120,26. El aviso incluye la representación habitual de que la persona vendedora no tiene conocimiento de información material adversa no divulgada.

10x Genomics (TXG)는 Form 144를 제출하여 Rule 144에 따라 7,393주의 보통주를 총 $99,140.13의 시가로 매도할 예정임을 보고했으며, 매각은 2025-08-22에 NASDAQ을 통해 Morgan Stanley Smith Barney LLC에서 이루어질 예정입니다.

해당 주식은 발행사로부터 2025-08-21Restricted Stock Unit으로 부여된 총 20,657단위이며 제공한 서비스에 대한 보수로 지급되었습니다. 보고자는 또한 2025-05-227,485주를 매도하여 총수입 $62,120.26을 확보했습니다. 통지서에는 매도인이 미공개된 중대한 불리한 정보를 알고 있지 않다는 표준 진술이 포함되어 있습니다.

10x Genomics (TXG) a déposé un formulaire 144 signalant la vente proposée en vertu de la règle 144 de 7 393 actions ordinaires pour une valeur de marché totale de 99 140,13 $, prévue le 22/08/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC.

Les actions ont été attribuées comme Restricted Stock Unit par l'émetteur le 21/08/2025 pour un total de 20 657 unités et versées en tant que rémunération pour services rendus. Le déclarant a également vendu 7 485 actions le 22/05/2025 pour des produits bruts de 62 120,26 $. L'avis inclut la déclaration habituelle selon laquelle la personne vendeuse n'a pas connaissance d'informations défavorables matériales non divulguées.

10x Genomics (TXG) hat ein Formular 144 eingereicht, in dem der geplante Verkauf gemäß Rule 144 von 7.393 Stammaktien mit einem Gesamtmarktwert von $99.140,13 gemeldet wird. Der Verkauf ist für den 22.08.2025 an der NASDAQ über Morgan Stanley Smith Barney LLC vorgesehen.

Die Aktien wurden dem Emittenten zufolge am 21.08.2025 als Restricted Stock Unit-Zuteilung in Höhe von insgesamt 20.657 Einheiten gewährt und als Vergütung für erbrachte Dienstleistungen ausgezahlt. Der Melder verkaufte außerdem am 22.05.2025 7.485 Aktien und erzielte Bruttoerlöse in Höhe von $62.120,26. Die Mitteilung enthält die übliche Zusicherung, dass die verkaufende Person nicht über nicht offen gelegte, wesentlich nachteilige Informationen Kenntnis hat.

Positive
  • Clear disclosure of broker, share count, and aggregate market value facilitates market transparency
  • Securities originated from an RSU grant, indicating the sale is monetization of compensation rather than a secondary capital raise
Negative
  • Insider selling activity of 7,393 shares valued at $99,140.13 could modestly increase floating supply
  • No trading-plan date disclosed in the filing, so the sale does not show an explicit Rule 10b5-1 adoption date

Insights

TL;DR: Insider plans to sell roughly $99k of newly vested RSU shares; transaction appears routine and follows prior small sale.

The Form 144 discloses a proposed Rule 144 sale of 7,393 common shares valued at about $99k, sourced from a Restricted Stock Unit grant delivered one day earlier. The close timing between grant/vesting and the proposed sale is documented here, and a prior sale of 7,485 shares in May for $62k is also reported. From a trading-impact perspective this is modest relative to typical market caps for publicly listed life sciences equipment companies; the filing signals routine monetization of compensation rather than a major liquidity event.

TL;DR: Disclosure complies with Rule 144 mechanics; the filer affirms absence of undisclosed material information.

The notice records the required broker, share counts, and acquisition history tied to an RSU grant, meeting Form 144 disclosure obligations. The signature representation about no material non-public information is included. This filing documents insider selling activity consistent with standard post-vesting disposal; there is no disclosure here of any trading-plan adoption date or other governance details that would indicate a pre-established sale program.

10x Genomics (TXG) ha presentato un modulo 144 segnalando la prevista vendita, ai sensi della Rule 144, di 7.393 azioni ordinarie per un valore di mercato complessivo di $99.140,13, programmata per il 22/08/2025 su NASDAQ tramite Morgan Stanley Smith Barney LLC.

Le azioni sono state assegnate come Restricted Stock Unit dall'emittente il 21/08/2025 per un totale di 20.657 unità e corrisposte come compenso per servizi resi. Il dichiarante aveva inoltre venduto 7.485 azioni il 22/05/2025 per proventi lordi di $62.120,26. L'avviso include la consueta dichiarazione che la persona venditrice non è a conoscenza di informazioni riservate sfavorevoli non divulgate.

10x Genomics (TXG) presentó un Formulario 144 informando de la venta propuesta bajo la Regla 144 de 7.393 acciones ordinarias por un valor de mercado agregado de $99,140.13, prevista para el 22/08/2025 en NASDAQ a través de Morgan Stanley Smith Barney LLC.

Las acciones fueron otorgadas como Restricted Stock Unit por el emisor el 21/08/2025, por un total de 20.657 unidades y pagadas como compensación por servicios prestados. El declarante también vendió 7.485 acciones el 22/05/2025 por ingresos brutos de $62.120,26. El aviso incluye la representación habitual de que la persona vendedora no tiene conocimiento de información material adversa no divulgada.

10x Genomics (TXG)는 Form 144를 제출하여 Rule 144에 따라 7,393주의 보통주를 총 $99,140.13의 시가로 매도할 예정임을 보고했으며, 매각은 2025-08-22에 NASDAQ을 통해 Morgan Stanley Smith Barney LLC에서 이루어질 예정입니다.

해당 주식은 발행사로부터 2025-08-21Restricted Stock Unit으로 부여된 총 20,657단위이며 제공한 서비스에 대한 보수로 지급되었습니다. 보고자는 또한 2025-05-227,485주를 매도하여 총수입 $62,120.26을 확보했습니다. 통지서에는 매도인이 미공개된 중대한 불리한 정보를 알고 있지 않다는 표준 진술이 포함되어 있습니다.

10x Genomics (TXG) a déposé un formulaire 144 signalant la vente proposée en vertu de la règle 144 de 7 393 actions ordinaires pour une valeur de marché totale de 99 140,13 $, prévue le 22/08/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC.

Les actions ont été attribuées comme Restricted Stock Unit par l'émetteur le 21/08/2025 pour un total de 20 657 unités et versées en tant que rémunération pour services rendus. Le déclarant a également vendu 7 485 actions le 22/05/2025 pour des produits bruts de 62 120,26 $. L'avis inclut la déclaration habituelle selon laquelle la personne vendeuse n'a pas connaissance d'informations défavorables matériales non divulguées.

10x Genomics (TXG) hat ein Formular 144 eingereicht, in dem der geplante Verkauf gemäß Rule 144 von 7.393 Stammaktien mit einem Gesamtmarktwert von $99.140,13 gemeldet wird. Der Verkauf ist für den 22.08.2025 an der NASDAQ über Morgan Stanley Smith Barney LLC vorgesehen.

Die Aktien wurden dem Emittenten zufolge am 21.08.2025 als Restricted Stock Unit-Zuteilung in Höhe von insgesamt 20.657 Einheiten gewährt und als Vergütung für erbrachte Dienstleistungen ausgezahlt. Der Melder verkaufte außerdem am 22.05.2025 7.485 Aktien und erzielte Bruttoerlöse in Höhe von $62.120,26. Die Mitteilung enthält die übliche Zusicherung, dass die verkaufende Person nicht über nicht offen gelegte, wesentlich nachteilige Informationen Kenntnis hat.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the Form 144 filed for TXG report?

The filing reports a proposed Rule 144 sale of 7,393 TXG common shares with an aggregate market value of $99,140.13 to be executed on 08/22/2025 on NASDAQ.

How were the shares being sold acquired?

The shares were acquired as a Restricted Stock Unit grant from the issuer on 08/21/2025, totaling 20,657 units, with payment listed as services rendered.

Who is the broker handling the sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Services, with the address shown in Sandy, UT.

Has the filer sold TXG shares recently?

Yes. The filer sold 7,485 common shares on 05/22/2025 for gross proceeds of $62,120.26.

Does the filing state there is undisclosed material information?

The filer affirms by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed.
10X Genomics, Inc.

NASDAQ:TXG

TXG Rankings

TXG Latest News

TXG Latest SEC Filings

TXG Stock Data

1.66B
112.26M
1.87%
105.23%
11.61%
Health Information Services
Laboratory Analytical Instruments
Link
United States
PLEASANTON